We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.67B
AUM Growth
+$41.2M
Cap. Flow
+$7.87M
Cap. Flow %
0.29%
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$32.1M
2
ILMN icon
Illumina
ILMN
+$23.5M
3
STE icon
Steris
STE
+$18.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$16.2M
5
HUM icon
Humana
HUM
+$15.1M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.9M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.6M
3
UNH icon
UnitedHealth
UNH
+$29M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21M
5
CVS icon
CVS Health
CVS
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.21%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAH
76
DELISTED
PRA Health Sciences, Inc.
PRAH
$8.07M 0.3%
79,526
-63,982
-45% -$6.52M
RARE icon
77
Ultragenyx Pharmaceutical
RARE
$2.54B
$8.01M 0.3%
97,480
– –
KYNB
78
Kyntra Bio
KYNB
$27.4M
$7.99M 0.3%
7,771
– –
CCXI
79
DELISTED
ChemoCentryx, Inc.
CCXI
$7.92M 0.3%
+144,447
New +$7.78M
COR icon
80
Cencora
COR
$59.6B
$7.82M 0.29%
80,645
– –
MOH icon
81
Molina Healthcare
MOH
$10.2B
$7.81M 0.29%
42,669
+15,133
+55% +$2.75M
DXCM icon
82
DexCom
DXCM
$32.9B
$7.64M 0.29%
74,176
+45,172
+156% +$4.72M
RETA
83
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$7.45M 0.28%
76,440
+25,533
+50% +$3.19M
MPT
84
Medical Properties Trust
MPT
$2.78B
$7.26M 0.27%
411,743
– –
TEVA icon
85
Teva Pharmaceuticals
TEVA
$40.1B
$7.08M 0.27%
785,851
– –
SBRA icon
86
Sabra Healthcare REIT
SBRA
$5.2B
$7.04M 0.26%
510,660
– –
CRL icon
87
Charles River Laboratories
CRL
$11.3B
$6.96M 0.26%
30,754
+12,287
+67% +$2.55M
GMAB icon
88
Genmab
GMAB
$17.6B
$6.76M 0.25%
184,779
+168,259
+1,019% +$6.08M
AGIO icon
89
Agios Pharmaceuticals
AGIO
$1.82B
$6.54M 0.25%
186,964
– –
APLS
90
DELISTED
Apellis Pharmaceuticals
APLS
$6.52M 0.24%
216,017
+42,523
+25% +$1.27M
STRO icon
91
Sutro Biopharma
STRO
$416M
$6.45M 0.24%
64,127
– –
UTHR icon
92
United Therapeutics
UTHR
$22B
$6.42M 0.24%
63,513
– –
CRSP icon
93
CRISPR Therapeutics
CRSP
$5.23B
$6.38M 0.24%
76,222
– –
TRIL
94
DELISTED
Trillium Therapeutics Inc.
TRIL
$6.37M 0.24%
448,049
– –
LTC
95
LTC Properties
LTC
$1.99B
$6.36M 0.24%
182,293
– –
NBIX icon
96
Neurocrine Biosciences
NBIX
$16.9B
$6.08M 0.23%
63,203
-142,947
-69% -$16.5M
ZGNX
97
DELISTED
Zogenix, Inc.
ZGNX
$5.98M 0.22%
333,402
+117,996
+55% +$2.89M
CERN
98
DELISTED
Cerner Corp
CERN
$5.89M 0.22%
81,500
– –
SAGE
99
DELISTED
Sage Therapeutics
SAGE
$5.88M 0.22%
96,211
– –
TFX icon
100
Teleflex
TFX
$6.18B
$5.87M 0.22%
17,252
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tekla Capital Management held 233 positions worth $2.67B, up 1.6% from $2.63B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q3 2020 filing shows 11 new, 50 increased, 32 reduced and 29 closed positions. Its largest new stake was ChemoCentryx, Inc.: 144,447 shares worth $7.92M. The largest sale was Johnson & Johnson, an estimated $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2020 buy was ChemoCentryx, Inc.: 144,447 shares worth $7.92M.
  • Tekla Capital Management added most to AbbVie in Q3 2020, an estimated $32.1M increase.
  • Tekla Capital Management's biggest Q3 2020 reduction was Johnson & Johnson, cutting an estimated $41.9M.
  • Tekla Capital Management fully exited Allogene Therapeutics in Q3 2020, selling an estimated $9.25M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $2.67B portfolio in Q3 2020.
  • Tekla Capital Management opened 11 new positions and closed 29 in Q3 2020.
  • Tekla Capital Management's portfolio value rose 1.6% quarter-over-quarter to $2.67B.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.